Comparison and optimal use of fixed combinations in the management of COPD

International Journal of COPD

Volumn 2, Issue 2, 2007, Pages 107-116

  Mensing, Mirjam ^a   Aalbers, René ^a  

^a MARTINI HOSPITAL   (Netherlands)

Author keywords

COPD; Inhaled corticosteroids; Long acting 2 agonists

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PLACEBO; SALMETEROL; TERBUTALINE;

ANTIINFLAMMATORY ACTIVITY; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTERMETHOD COMPARISON; MAINTENANCE DRUG DOSE; METERED DOSE INHALER; MONOTHERAPY; NEBULIZER; OROPHARYNX CANDIDIASIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POWDER INHALER; QUALITY OF LIFE; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANDROSTADIENES; BRONCHOCONSTRICTOR AGENTS; BUDESONIDE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; HUMANS; NEBULIZERS AND VAPORIZERS; PATIENT COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 34547630554     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Aalbers R, Backer V, Kava TT, et al. 2004. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/ fluticasone in moderate to severe asthma. Curr Med Res Opin, 20:225-40.
2. Balzano G, Battiloro R, Biraghi M, et al. 2000. Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients with chronic airflow obstruction: metered dose inhaler versus jet nebulizer. J Aerosol Med, 13:25-33.
3. Barnes NC, Qiu YS, Pavord ID, et al. 2006. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med, 173:736-43.
4. Bourbeau J, Julien M, Maltais F, et al. 2003. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med, 163:585-91.
5. Brodde OE, Howe U, Egerszegi S, et al. 1988. Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators. Eur J Clin Pharmacol, 34:145-50.
6. [BTS] British Thoracic Society. 1997. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax, 52:S1-28.
7. Burnell PK, Small T, Doig S, et al. 2001. Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir Med, 95:324-30.
8. Calverley P, Pauwels R, Jones P, et al. 2006. The severity of airway obstruction as a determinant of treatment response in COPD. Int J COPD, 1:209-18.
9. Calverley P, Pauwels R, Vestbo J, et al. 2003a. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 361:449-56.
10. Calverley PM. 2004. Effect of corticosteroids on exacerbations of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc, 1:161-6.
11. Calverley PM, Boonsawat W, Cseke Z, et al. 2003b. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 22: 912-19.
12. Campbell M, Eliraz A, Johansson G, et al. 2005. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med, 99:1511-20.
13. Cazzola M, Santus P, Di Marco MF, et al. 2003. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med, 97:453-7.
14. Celli BR, MacNee W. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23:932-46.
15. Dal Negro RW, Pomari C, Tognella S, et al. 2003. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther, 16:241-6.
16. Gizycki MJ, Hattotuwa KL, Barnes N, et al. 2002. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax, 57:799-803.
17. [GSK] GlaxoSmithKline. 2006. Press release [online]. Accessed 30 June 2006. URL: http://www.gsk.com.
18. [GOLD] Global Inititive for Chronic Obstructive Lung Disease. 2006. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: executive summary (updated 2006) [online]. Accessed 1 June 2007. URL: http://www.goldcopd.org.
19. Gosman MME, Lapperre TS, Snoeck-Stroband JB, et al. 2006. Effect of 6 month therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD [abstract]. ATS conference, A111.
20. Hanania NA, Darken P, Horstman D, et al. 2003. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest, 124:834-843.
21. Haque RA, Torrego A, Essilfie-Quaye S, et al. 2006. Effects of salmeterol and fluticasone on glucocorticoid receptor translocation in sputum macrophages and peripheral blood mononuclear cells from patients with chronic obstructive pulmonary disease [abstract]. ATS conference, A848.
22. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. 2002. The effects of inhaled. fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med, 165:1592-6.
23. Haughney J, Barnes G, Partridge M, et al. 2004. The Living & Breathing Study: a study of patients' views of asthma and its treatment. Prim Care Respir J, 13:28-35.
24. Haynes RB, Yao X, Degani A, et al. 2005. Interventions to enhance medication adherence. Cochrane Database Syst Rev, 4:CD000011.
25. Hutchinson AF, Thompson MA, Brand CA, et al. 2006. Patient self-management training and a nurse-led rapid assessment service in the community decreases severity of exacerbations and readmission rates in the Melbourne Longitudinal COPD Cohort (MLCC) [abstract]. ATS conference, A811.
26. Jeffery PK, Venge P, Gizycki MJ, et al. 2002. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J, 20:1378-85.
27. Lipworth BJ, Fardon TC. 2004. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol, 113:178-9.
28. Mahler DA, Wire P, Horstman D, et al. 2002. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 166:1084-91.
29. Mak JC, Nishikawa M, Barnes PJ. 1995b. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol, 268:L41-6.
30. Mak JC, Nishikawa M, Shirasaki H, et al. 1995a. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest, 96:99-106.
31. Mapel DW, Hurley JS, Roblin D, et al. 2006a. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir Med, 100:595-609.
32. Mapel DW, Nelson LS, Lydick E, et al. 2006b. Survival of COPD patients using the Advair (R) diskus, inhaled corticosteroids and salmeterol individually, inhaled corticosteroids alone, or short acting bronchodilators alone [abstract]. ATS conference, A110.
33. Metcalfe S, Moodie P. 2004. Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices. J Allergy Clin Immunol, 113:568-9.
34. Monninkhof E, van der Valk P J, van der Palen J et al. 2003. Self-management education for patients with chronic obstructive pulmonary disease: a systematic review. Thorax, 58:394-8.
35. Nannini L, Cates CJ, Lassetson TJ, et al. 2004. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3:CD003794.
36. Nelson HS, Chapman KR, Pyke SD, et al. 2003. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol, 112:29-36.
37. [NICE] National Institute for Clinical Excellence. 2004. Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secudary care. Thorax, 59(Suppl I).
38. O'Byrne PM, Bisgaard H, Godard PP, et al. 2005. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med, 171:129-36.
39. Seemungal TA, Donaldson GC, Bhowmik A, et al. 2000. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 161:1608-13.
40. Seemungal TA, Donaldson GC, Paul EA, et al. 1998. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 157:1418-22.
41. Singh D. 2006. The benefits of combined treatment with corticosteroids and long-acting beta agonists. Int J COPD, 1:207-8.
42. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, et al. 2005. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax, 60:925-31.
43. Soriano JB, Kiri VA, Pride NB, et al. 2003. Inhaled corticosteroids with/ without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med, 2:67-74.
44. Stoloff SW, Stempel DA, Meyer J, et al. 2004. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 113:245-51.
45. Suissa S. 2006. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 173:842-6.
46. Szafranski W, Cukier A, Ramirez A, et al. 2003. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J, 21:74-81.
47. Toelle BG, Ram FS. 2004. Written individualised management plans for asthma in children and adults. Cochrane Database Syst Rev, 2: CD002171.
48. van der Palen J, Klein JJ, Schildkamp AM. 1998. Comparison of a new multidose powder inhaler (Diskus/Accuhaler) and the Turbuhaler regarding preference and case of use. J Asthma, 35:147-52.
49. van der Woude H J, Boorsma M, Bergqvist PB, et al. 2004. Budesonide/ formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther, 17:89-95.
50. van Grunsven PM, van Schayck CP, van Deuveren M, et al. 2000. Compliance during long-term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study. J Asthma, 37:225-34.
51. Vestbo J. 2004. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J, 24:206-10.
52. Wallin A, Sandstrom T, Soderberg M, et al. 1999. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med, 159:79-86.
53. Wedzicha JA, Donaldson GC. 2003. Exacerbations of chronic obstructive pulmonary disease. Respir Care, 48:1204-13.
54. Wouters EF, Postma DS, Fokkens B, et al. 2005. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax, 60:480-7.
55. Yamauchi Y, Christodoulopoulos P, Maltais F, et al. 2006. The effect of salmeterol/fluticasone combination on airway inflammation in COPD compared to fluticasone [abstract]. ATS conference, A113.
56. Zetterstrom O, Buhl R, Mellem H, et al. 2001. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J, 18:262-8.